REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2021.07.21 | 07:00 | Permanent Information Releases / General Company News

puce Novartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert - HTML (w)

2021.07.21 | 07:00 | Permanent Information Releases / General Company News

puce Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged. - HTML (w)

2021.07.21 | 07:00 | Permanent Information Releases / General Company News

puce Novartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées - HTML (w)

2021.07.20 | 13:05 | Permanent Information Releases / General Company News

puce Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity - HTML (w)

2021.06.28 | 07:00 | Permanent Information Releases / Appointments

puce Novartis appoints Rob Kowalski as Chief People & Organization Officer - HTML (w)

2021.06.18 | 18:30 | Permanent Information Releases / General Company News

puce New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline - HTML (w)

2021.06.11 | 09:00 | Permanent Information Releases / General Company News

puce Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria - HTML (w)

2021.06.06 | 12:06 | Permanent Information Releases / General Company News

puce Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) - HTML (w)

2021.06.04 | 15:05 | Permanent Information Releases / General Company News

puce Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC - HTML (w)

2021.06.04 | 15:00 | Permanent Information Releases / General Company News

puce Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy - HTML (w)

2021.06.03 | 23:05 | Permanent Information Releases / General Company News

puce Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera - HTML (w)

2021.06.03 | 18:04 | Permanent Information Releases / General Company News

puce Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study - HTML (w)

2021.06.02 | 15:05 | Permanent Information Releases / General Company News

puce Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma - HTML (w)

2021.06.02 | 15:00 | Permanent Information Releases / General Company News

puce Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients - HTML (w)

2021.06.02 | 07:15 | Permanent Information Releases / Sales and Revenues

puce Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021 - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1426